Case report: Fast disease progression during adjuvant therapy with anti-PD-1 in stage III melanoma patients.

ABSTRACT:

Background

Stage III surgically resected melanoma is a disease at high risk of recurrence. Immune checkpoint inhibitors (ICIs) and the target therapy with BRAF and MEK inhibitors significantly changed the outcome of patients with metastatic melanoma and several studies have also shown their benefit in the adjuvant setting for the delay of recurrence in stage III melanoma patients. Hyperprogression disease was observed as a possible adverse response to immunotherapy in the metastatic setting, suggesting that some patients could face additional risk of progression with ICIs, although no consensus was found for the correct definition of this event.

Case presentation

We describe here two cases of rapid multiorgan metastatization during adjuvant immunotherapy in patients with sta

SUBMITTER: Di Pietro FR 

PROVIDER: S-EPMC11324500 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature